Teva reports in 1st-qtr 2025 with key innovative medicines growing ~40%
Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025.
First-quarter 2025 revenues of $3.9 billion saw an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%, versus the consensus estimate of $3.98 billion.
On a non-generally accepted accounting principles (GAAP) basis, diluted earnings per share (EPS) were $0.52, an increase of $0.04 or 8% year-over-year, surpassing the consensus estimate of $0.48. Gross profit in the quarter was $1,877 million, an increase of 6% compared to $1,771 million in the first quarter of 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze